Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?
about
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerExternal beam radiotherapy for localized prostate cancerComparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis.Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancerHigh-dose-rate brachytherapy boost for prostate cancer: rationale and techniqueUse of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009.Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancerThe impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer.New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect.High-risk prostate cancer-classification and therapy.Correlation between patients' anatomical characteristics and interfractional internal prostate motion during intensity modulated radiation therapy for prostate cancer.Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?Proton Beams Inhibit Proliferation of Breast Cancer Cells by Altering DNA Methylation StatusCan we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-upTargeted radiotherapy enhancement during electronic brachytherapy of accelerated partial breast irradiation (APBI) using controlled release of gold nanoparticlesRadiotherapy and Hormone Treatment in Prostate CancerMaintaining prostate contouring consistency following an educational interventionWhole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report.Racial Disparity in Prostate Cancer-Specific Mortality for High-Risk Prostate Cancer: A Population-Based Study.Outcomes of high-dose intensity-modulated radiotherapy alone with 1 cm planning target volume posterior margin for localized prostate cancer.Pharmacotherapeutic management of locally advanced prostate cancer: current status.Defining a dose-response relationship for prostate external beam radiotherapy.Proton beam and prostate cancer: An evolving debate.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Targeted radiotherapy with gold nanoparticles: current status and future perspectives.Clinical Outcomes of CyberKnife Radiotherapy in Prostate Cancer Patients: Short-term, Single-Center ExperienceBrachytherapy application with in situ dose painting administered by gold nanoparticle eluters.Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know.The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer.An image-based method to quantify biomechanical properties of the rectum in radiotherapy of prostate cancer.
P2860
Q26739738-4AB1DF45-B56F-4603-AC9F-E1B8DEC9FE6BQ26853068-9CBACCCB-8389-47D9-A78C-C0A178DB11EFQ33626084-707856D5-71C3-4BB0-8626-68D2857E883CQ33679365-AF0D8635-318B-4931-A6F7-82785FCFBAFBQ33725640-E1B546B8-57CB-4EF6-B4A6-5FF7388EC8D4Q34355194-D658B7A9-2965-48DE-9A49-25B7819FE478Q34988813-F9F0B350-DB27-4A8A-97DC-A8228EAE0F68Q35064458-40C12755-E7B1-4C49-AA04-AF21814F419DQ35115736-21A363D5-23DC-44A2-977D-BD2D32405622Q35141519-C4DCFFE6-0B15-4F25-9214-8839616A2846Q35235550-663CC2A3-804A-4A95-8787-B91348A41479Q35400436-BEE7A0B0-72A3-46A9-8A5C-8B6B4F121107Q35577274-ECDB99F8-8145-4757-A634-DC805ED9CF82Q35821336-96B9BC8E-2588-454B-857C-E5AB7CCF8B9CQ35869811-44C78227-D48F-434C-84AF-827314C8ED3EQ36234065-CFB8AF8A-A2AD-4812-AA7D-90273B0B3EA0Q36474222-E91416E1-3CC2-447C-BB8F-8E73A4AF4EFBQ36520539-B41B8A6D-4CAE-46E4-9FF0-2236FCF78EFDQ36563924-859B8C2A-2D95-4C59-81BA-A870F5C3FD5FQ36726123-A0AA19B0-9AB3-4FF1-9ACD-984A8838E56CQ36874598-123FEC43-DA15-443A-881B-C04A867382E6Q36908059-FF9F9E18-3217-4488-9D61-04248D726596Q37081939-8A412785-8E34-48F8-B120-28E9BF747DF6Q37097954-C8C21B65-DFB7-42FD-85B8-6682F3262B09Q37176612-5F88149A-8801-4271-AC73-432FC2DFD48FQ37243120-21345456-48B0-406E-98C1-1B6A6365DAA1Q37549491-8F9B9D76-7CC1-4967-8D90-15FB264928BDQ37624321-AB8570CA-8EDE-4D4F-A0D4-83507CFDF884Q37717598-50C3F8CC-2082-4992-BEB6-34A342D2E410Q37888666-83ED17FF-DEB9-4D12-873D-553C1099192FQ38095668-F6DDBB12-35B5-45ED-AACB-1762382FFFFBQ38177807-78E855EF-ACD7-4B6E-8151-72B8B4DBD56AQ38180344-D6134340-B410-4CB3-BB42-6A32780A70F0Q38224610-525977DD-757A-4E6B-9935-BF9844A834DEQ38306112-FAB41E8E-E569-4BFF-B1DD-E348297FDF50Q38417415-1E296FEB-CBDB-4C10-A7A4-DE7999661165Q38636446-C0F0B8BE-3911-4DEE-9CCF-18FCF922BCAAQ38851017-200C6A6B-C746-43D5-9641-BC5A8EAE9A72Q38910225-0619ADCE-42A6-48B2-8347-106943080CE1Q38982334-47766A86-706C-4E38-947A-B6D6CB710562
P2860
Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Long-term failure patterns and ...... e cancer. Who dies of disease?
@en
Long-term failure patterns and ...... e cancer. Who dies of disease?
@nl
type
label
Long-term failure patterns and ...... e cancer. Who dies of disease?
@en
Long-term failure patterns and ...... e cancer. Who dies of disease?
@nl
prefLabel
Long-term failure patterns and ...... e cancer. Who dies of disease?
@en
Long-term failure patterns and ...... e cancer. Who dies of disease?
@nl
P2093
P1476
Long-term failure patterns and ...... e cancer. Who dies of disease?
@en
P2093
Alan Pollack
Andrew K Lee
Deborah A Kuban
Lawrence B Levy
M Rex Cheung
Seungtaek Choi
Steven Frank
P304
P356
10.1016/J.IJROBP.2010.01.006
P407
P577
2010-05-20T00:00:00Z